Vizimpro Tablet, Film Coated
Product Images NDC 0069-0197

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Vizimpro (NDC 0069-0197). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pfizer Laboratories Div Pfizer Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Vizimpro 01)

Chemical structure diagram of dacomitinib monohydrate, the active ingredient in Vizimpro, showing its molecular components including a fluorine and chlorine-substituted aromatic ring, methoxy group, and piperidine ring.*

FDA Label Image

Figure 1 (Vizimpro 02)

A progression-free survival Kaplan-Meier curve comparing Vizimpro (dacomitinib) to Gefitinib over 48 months. The y-axis shows the probability of progression-free survival, and the x-axis shows time in months. Vizimpro is represented by a solid black line, while Gefitinib is a dashed gray line. The graph includes numbers at risk for both drugs at several time points.*

FDA Label Image

Figure 2 (Vizimpro 03)

A Kaplan-Meier survival curve graph comparing overall survival probability over time (months) between Vizimpro and Gefitinib. The x-axis represents overall survival in months up to 48 months, and the y-axis shows the probability of overall survival from 0.0 to 1.0. Two survival curves are plotted: a solid black line for Vizimpro and a dashed gray line for Gefitinib, with patient numbers at risk listed below the x-axis at various time points. Censored patient data are indicated with plus marks on the curves.*

FDA Label Image

Logo (Vizimpro 04)

FDA Label Image

Logo (Vizimpro 05)

FDA Label Image

Principal Display Panel (15 mg Tablet Bottle Label)

Vizimpro (dacomitinib) tablets 15 mg film-coated oral tablets label shows Pfizer as the labeler. The label includes storage instructions, dosage note stating each tablet contains 15 mg dacomitinib, a package count of 30 tablets, and a National Drug Code (NDC) number 0069-0197-30. It states the product is for prescription use only and made in Ireland.*

FDA Label Image

Principal Display Panel (30 mg Tablet Bottle Label)

Label for Vizimpro (dacomitinib) tablets, 30 mg strength. The film-coated tablets are distributed by Pfizer Labs, a division of Pfizer Inc. The package contains 30 tablets for oral use. The label includes storage instructions, dosage reference, and states the product is made in Ireland.*

FDA Label Image

Principal Display Panel (45 mg Tablet Bottle Label)

Label for Vizimpro 45 mg (dacomitinib) tablets by Pfizer Laboratories. The label indicates the product contains 30 film-coated tablets for oral use, with storage instructions between 20°C to 25°C. It is distributed by Pfizer Labs, Division of Pfizer Inc, and made in Ireland. The label includes NDC 0069-2299-30 and barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.